US generic drugmaker Mylan (Nasdaq: MYL) posted disappointing profits ahead of the company's proposed hostile acquisition of Perrigo.
Profits fell 51% this quarter to $56.6 million, down from $115.9 million that Mylan reported for the first quarter of 2014. The company blamed this on costs related to the acquisition of part of Abbott Laboratories’ (NYSE: ABT) non-US operations. Revenue for the quarter climbed 9% to $1.87 billion from $1.72 billion.
Earnings per share fell 55% down to $0.13 from $0.29 in the same period of 2014. Without special items, adjusted profits rose 6% to $0.70 per share, in line with analysts’ estimates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze